{"id":20,"date":"2015-03-06T18:11:08","date_gmt":"2015-03-06T18:11:08","guid":{"rendered":"http:\/\/labs.icahn.mssm.edu\/villanueva-lab\/?page_id=20"},"modified":"2019-05-09T15:36:08","modified_gmt":"2019-05-09T15:36:08","slug":"publications","status":"publish","type":"page","link":"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/publications\/","title":{"rendered":"PUBLICATIONS"},"content":{"rendered":"<p><a href=\"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-content\/uploads\/sites\/127\/2015\/03\/publications-strip.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-74\" src=\"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-content\/uploads\/sites\/127\/2015\/03\/publications-strip.jpg\" alt=\"\" width=\"1270\" height=\"63\" srcset=\"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-content\/uploads\/sites\/127\/2015\/03\/publications-strip.jpg 1270w, https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-content\/uploads\/sites\/127\/2015\/03\/publications-strip-300x15.jpg 300w, https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-content\/uploads\/sites\/127\/2015\/03\/publications-strip-1024x51.jpg 1024w\" sizes=\"auto, (max-width: 1270px) 100vw, 1270px\" \/><\/a><\/p>\n<p><strong>\u00a0<\/strong><\/p>\n<p><strong>2019<\/strong><\/p>\n<ul>\n<li><u>Villanueva A<\/u>. Hepatocellular Carcinoma. <strong>N Engl J Med<\/strong> 2019 (in press)<\/li>\n<li>Kenny TC, Craig AJ, <u>Villanueva A<\/u>, Germain D. Mitohormesis primes tumor invasion and metastasis. <strong>Cell Reports<\/strong> 2019 (in press)<\/li>\n<li>DeRossi C, Bambino K, Morrison J, Sakarin I, Villacorta-Martin C, Zhang C, Ellis JL, Fiel MI, Ybanez M, Lee YA, Huang KL, Yin C, Sakaguchi TF, Friedman SL, <u>Villanueva A<\/u>, Chu J. Mannose Phosphate Isomerase and Mannose Regulate Hepatic Stellate Cell Activation and Fibrosis in Zebrafish and Humans. <strong>Hepatology<\/strong> 2019 (in press)<\/li>\n<li>Puigvehi M, Moctezuma C, <u>Villanueva A<\/u>, Llovet JM. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. <strong>JHEP reports<\/strong> 2019 (in press)<\/li>\n<li>Slocum E, Craig A, <u>Villanueva A<\/u>, Germain D. Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. <strong>Breast Cancer Res<\/strong>. 2019 (in press)<\/li>\n<li>Yu JX, Craig A, Duffy M, Villacorta-Martin C, Miguela V, Ruiz-de-Galarreta M, Scopton AP, Silber L, Maldonado AY, Rialdi A, Guccione E, Lujambio A*, <u>Villanueva A<\/u>, Dar AC. <strong>Mol Cancer Ther<\/strong> 2019 (in press)<\/li>\n<li>Llovet JM, Montal R, <u>Villanueva A<\/u>. Randomized trials and endpoints in advanced hepatocellular carcinoma: Role of PFS as a surrogate of survival. <strong>J Hepatol<\/strong> 2019 (in press)<\/li>\n<li>Martins-Filho SN, Alves VAF, Wakamatsu A, Maeda M, Craig AJ, Villacorta-Martin C, D\u2019Avola D, Labgaa I, Carrilho FJ, Thung SN, <u>Villanueva A.<\/u> A phenotypic map of disseminated hepatocellular carcinoma suggests clonal constraints in metastatic sites. <strong>Histopathology<\/strong> 2019 (in press)<\/li>\n<\/ul>\n<p><strong>2018<\/strong><\/p>\n<ul>\n<li>von Felden J, Craig AJ, <u>Villanueva A<\/u>. Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma. <strong>Oncoscience<\/strong>. 2018 (in press)<\/li>\n<li>D&#8217;Avola D, Villacorta-Martin C, Martins-Filho SN, Craig AJ, Labgaa I, von Felden J, Allette K, Bonaccorso A, Tabrizian P, Hartmann BN, Sebra R, Schwartz M, Villanueva A. High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma. <strong>Sci Rep<\/strong> 2018 (in press).<\/li>\n<li>Labgaa I*, Villacorta-Martin C*, D\u2019Avola D, Craig AJ, von Felden J, Martins-Filho S, Sia D, Stueck A, Ward SC, Fiel MI, Mahajan M, Tabrizian P, Thung SN, Ang C, Friedman SL, Llovet JM, Schwartz M, Villanueva A. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. <strong>Oncogene<\/strong> 2018 (in press).<\/li>\n<li>Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau G, Mazzaferro V, Roayaie S, Lee HC, Kokudo N, Zhag Z, Torrecilla S, Moeini A, Rodriguez-Carunchio L, Gene E, Verslype C, Croitoru AE, Cillo U, de la Mata M, Lupo L, Strasser S, Park JW, Camps J, Sole M, Thung S, Villanueva A, Pena C, Meinhardt G, Bruix J, Llovet JM. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. <strong>Gut<\/strong> 2018 (in press).<\/li>\n<\/ul>\n<p><strong>2017<\/strong><\/p>\n<ul>\n<li>Villacorta-Martin C, Craig AJ, Villanueva A. Divergent evolutionary trajectories in transplanted tumor models.<strong> Nat Genet.<\/strong> 2017 Oct 27;49(11):1565-1566.<\/li>\n<li>Craig AJ, von Felden J, Villanueva A. Molecular profiling of liver cancer heterogeneity. <strong>Discov Med.<\/strong> 2017;24(131):117-125.<\/li>\n<li>Torrecilla S, Sia D, Harrington AN, Zhang Z, Cabellos L, Cornella H, Moeini A, Camprecios G, Leow WQ, Fiel MI, Hao K, Bassaganyas L, Mahajan M, Thung SN, Villanueva A, Florman S, Schwartz ME, Llovet JM. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. <strong>J Hepatol.<\/strong> 2017;67(6):1222-1231<\/li>\n<li>Chiang DY, Villanueva A. Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation? <strong>J Hepatol<\/strong>. 2017;67(5):893-895.<\/li>\n<li>Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM. Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features. <strong>Gastroenterology<\/strong> 2017;153(3):812-826.<\/li>\n<li>Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva A, Thung SN, Schwartz ME, Llovet JM. Mixed hepatocellular-cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity. <strong>J Hepatol<\/strong> 2017;66(5):952-961.<\/li>\n<li>Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Sole M, Domingo-Domenech J, Villanueva A, Llovet JM. Tumour initiating cells and IGF\/FGF signaling contribute to sorafenib resistance in hepatocellular carcinoma. <strong>Gut<\/strong> 2017;66:952-961<\/li>\n<li>Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. <strong>Gastroenterology<\/strong> 2016;152:745-761<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>2016<\/strong><\/p>\n<ul>\n<li>Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis.\u00a0<strong>Gastroenterology<\/strong> 2016;152:745-761<\/li>\n<li>Nakagawa S, Wei L, Song WM, Higashi T, Ghoshal S, Kim RS, Bian CB, Yamada S, Sun X, Venkatesh A, Goossens N, Bain G, Lauwers GY, Koh AP, El-Abtah M, Ahmad NB, Hoshida H, Erstad DJ, Gunasekaran G, Lee Y, Yu ML, Chuang WL, Dai CY, Kobayashi M, Kumada H, Beppu T, Baba H, Mahajan M, Nair VD, Lanuti M, Villanueva A, Sangiovanni A, Iavarone M, Colombo M, Llovet JM, Subramanian A, Tager AM, Friedman SL, Baumert TF, Schwarz ME, Chung RT, Tanabe KK, Zhang B, Fuchs BC, Hoshida Y; Precision Liver Cancer Prevention Consortium. Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis<\/li>\n<li>Martinez-Quetglas I, Pinyol R, Dauch D, Torrecilla S, Tovar V, Moeini A, Alsinet C, Portela A, Rodriguez-Carunchio L, Sol\u00e9 M, Lujambio A, Villanueva A, Thung S, Esteller M, Zender L, Llovet JM. IGF2 Is up-regulated by epigenetic mechanisms in hepatocellular carcinomas and is an actionable oncogene product in experimental models. <strong>Gastroenterology<\/strong> 2016; 151:1192-1205<\/li>\n<li>Villanueva A, Luedde T. The transition from inflammation to cancer in the liver. <strong>Clinical Liver Disease<\/strong> 2016 (in press)<\/li>\n<li>D\u2019Avola D, Labgaa I, Villanueva A. Natural history of non-alcoholic steatohepatitis \/ non-alcoholic fatty liver disease \u2013 hepatocellular carcinoma: Magnitude of the problem from a Hepatology clinic perspective. <strong>Clinical Liver Disease<\/strong> 2016 (in press)<\/li>\n<li>Craig AJ, Villanueva A. Molecular-based signatures in hepatocellular carcinoma. <strong>Hepatology<\/strong> 2016; 63(6): 2018<\/li>\n<li>Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. <strong>J Hepatol <\/strong>2016 (in press)<\/li>\n<li>Wiegand J, van B\u00f6mmel F, Duarte-Rojo A, Altamirano J, Abraldes JG, Villanueva A, Berg T. Clinical Trial Watch: Reports from the Liver Meeting, AASLD, San Francisco, November 2015. <strong>J Hepatol<\/strong> 2016;64:1428-45<\/li>\n<li>Giovannoni R, Villanueva A. Circulating tumor cells and cholangiocarcinoma. <strong>Hepatology<\/strong> 2016;63:23-5.<\/li>\n<\/ul>\n<p><strong>\u00a02015<\/strong><\/p>\n<ul>\n<li>Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, Martinez-Quetglas I, Lozano JJ, Desbois-Mouthon C, Sole M, Domingo-Domenech J, Villanueva A, Llovet JM. Tumour initiating cells and IGF\/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. <strong>Gut<\/strong> 2015 (in press)<\/li>\n<li>Sia D, Moeini A, Labgaa I, Villanueva A. The future of patient-derived tumor xenografts in cancer treatment. <strong>Pharmacogenomics<\/strong> 2015;16:1671-83.<\/li>\n<li>Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. <strong>Gastroenterology <\/strong>2015;149:1226-1239.<\/li>\n<li>Gambato M, Villanueva A, Abraldes JG, Altamirano J, Forns X. Clinical Trial Watch: Reports from the EASL International Liver Congress (ILC), Vienna, April 2015. <strong>J Hepatol<\/strong> 2015;63:753-62.<\/li>\n<li>Lujambio A, Villanueva A. The usual SASPects of liver cancer. <strong>Aging<\/strong> 2015 (in press)<\/li>\n<li>Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. <strong>Nat Rev Clin Oncol<\/strong> 2015 (in press).<\/li>\n<li>Zhang DY, Goossens N, Guo J, Tsai MC, Chou HI, Altunkaynak C, Sangiovanni A, Ivarone M, Colombo M, Kobayashi M, Kumada H, Villanueva A, Llovet JM, Hoshida Y, Friedman SL. <strong>Gut<\/strong> 2015 (in press)<\/li>\n<li>Labgaa I, Villanueva A. Liquid biopsy in liver cancer.<strong> Discov Med<\/strong> 2015; 19:263-73<\/li>\n<li>Schulze K, Imbeaud S, Letouz\u00e9 E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Soysouvanh F, Calatayud AL, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc JF, Mazzaferro V, Calvo F, Villanueva A, Nault JC, Bioulac-Sage P, Stratton MR, Llovet JM, Zucman-Rossi J. Genomic landscape of hepatocellular carcinoma: from malignant transformation to therapeutic targets. <strong>Nat Genet<\/strong> 2015;47(5):505-511.<\/li>\n<li>Villanueva A, Portela A, Sayols S, Battiston C, Hoshida Y, Mendez-Gonzalez J, Imbeaud S, Letouze E, Hernandez-Gea V, Cornella H, Pinyol R, Sole M, Fuster J, Zucman-Rossi J, Mazzaferro V, Esteller M, Llovet JM. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. <strong>Hepatology<\/strong> 2015;61(6):1945-56.<\/li>\n<li>Nault JC, Villanueva A. Intra-tumor molecular and phenotypic diversity in hepatocellular carcinoma. <strong>Clin Cancer Res<\/strong> 2015;21(8):1786-8.<\/li>\n<\/ul>\n<p><strong>2014<\/strong><\/p>\n<ul>\n<li>Cornella H, Alsinet C, Sayols S, Zhang Z, Hao K, Cabellos L, Hoshida Y, Villanueva A, Thung S, Ward SC, Rodriguez-Carunchio L, Vila-Casadesus M, Imbeaud S, Lachenmayer A, Quaglia A, Nagorney DM, Minguez B, Carrilho F, Roberts LR, Waxman S, Mazzaferro V, Schwartz M, Esteller M, Heaton ND, Zucman-Rossi J, Llovet JM. <strong>Gastroenterology<\/strong> 2014;148(4):806-818.<\/li>\n<li>Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt A, Newell DR, Rose J, Manas DM, Shapiro GI, Curtin N, Reeves H. DNA- PK &#8211; a candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival. <strong>Clin Cancer Res<\/strong> 2014;21(4):925-33.<\/li>\n<li>King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, Deshmukh M, Venkatesh A, Tan PS, Sun X, Villanueva A, Sangiovanni A, Nair V, Mahajan M, Kobayashi M, Kumada H, Iavarone M, Colombo M, Fiel MI, Friedman SL, Llovet JM, Chung RT, Hoshida Y. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. <strong>Gut<\/strong> 2014 (in press).<\/li>\n<li>Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, Lachenmayer A, Revill K, Alsinet C, Sachidanandam R, Desai A, Senbanerjee S, Ukomadu C, Llovet JM, Sadler KC. UHRF1 as an oncogene in hepatocellular carcinoma. <strong>Cancer Cell<\/strong> 2014;25(2):196-209<\/li>\n<li>Pennycuick A, Suddle AR, Villanueva A. Transplantation for hepatocellular carcinoma. Worth waiting for? <strong>Liver Transpl<\/strong> 2014;20:871-3.<\/li>\n<li>Villanueva A, Llovet JM. Mutational landscape of HCC &#8211; the end of the beginning. <strong>Nat Rev Clin Oncol<\/strong> 2014;11:73-4.<\/li>\n<\/ul>\n<p><strong>2013<\/strong><\/p>\n<ul>\n<li>Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, Couchy G, Decaens T, Franco D, Imbeaud S, Rousseau F, Azoulay D, Saric J, Blanc JF, Balabaud C, Bioulac-Sage P, Laurent A, Laurent-Puig P, Llovet JM, Zucman-Rossi J. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. <strong>Gastroenterology<\/strong> 2013;145(1):176-87.<\/li>\n<li>Sia D, Alsinet C, Newell P, Villanueva A. VEGF signaling in cancer treatment. <strong>Curr Pharm Des<\/strong> 2013;20:2834-42<\/li>\n<li>Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene-expression signature for patients with hepatitis C-related early-stage cirrhosis. <strong>Gastroenterology<\/strong> 2013;144(5):1024-30.<\/li>\n<li>Alsinet C, Cornella H, Villanueva A. Genetically engineered mouse models: future tools to predict clinical trial results in oncology? <strong>Future Oncol<\/strong> 2013;9(6):767-70<\/li>\n<li>Villanueva A. Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach. <strong>J Hepatol<\/strong> 2013;59(2):392-5.<\/li>\n<li>Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, Cornella H, Klotzle B, Fan JB, Cotsoglou C, Thung SN, Fuster J, Waxman S, Garcia- Valdecasas JC, Bruix J, Schwartz ME, Beroukhim R, Mazzaferro V, Llovet JM. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals two subclasses with distinct clinical outcome. <strong>Gastroenterology<\/strong> 2013;144(4):829-40.<\/li>\n<li>Hernandez-Gea V, Turon F, Berzigotti A, Villanueva A. Management of small hepatocellular carcinoma in cirrhosis: focus on portal hypertension. <strong>World J Gastroenterol<\/strong> 2013;28:1193-9.<\/li>\n<li>Keng VW, Sia D, Sarver AL, Tschida BR, Fan D, Alsinet C, Sole M, Lee WL, Kuka TP, Moriarity BS, Villanueva A, Dupuy AJ, Riordan JD, Bell JB, T Silverstein KA, Llovet JM, Largaespada DA. Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR. <strong>Hepatology<\/strong> 2013;57:120-30.<\/li>\n<\/ul>\n<p><strong>2012<\/strong><\/p>\n<ul>\n<li>Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Sole M, Thung S, Stanger BZ, Llovet JM. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. <strong>Gastroenterology<\/strong> 2012;143(6):1660-1669.<\/li>\n<li>Lachenmayer A, Savic R, Alsinet C, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz ME, Friedman SL, Llovet JM. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. <strong>Clin Cancer Res<\/strong> 2012;18(18):4997-5007.<\/li>\n<li>Villanueva A, Llovet JM. Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma. <strong>Hepatology<\/strong> 2012;56(6):2416-9.<\/li>\n<li>Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. <strong>Nat Rev Gastro Hepat<\/strong> 2012;10(1):34-42.<\/li>\n<li>Vetter D, Cohen-Naftaly M, Villanueva A, Lee YA, Kocabayoglu P, Hannivoort R, Narla G, Llovet JM, Thung S, Friedman SL. Enhanced hepatocarcinogenesis in mouse models and human HCC by coordinate KLF6 depletion and increased mRNA splicing. <strong>Hepatology<\/strong> 2012;56(4):1361- 70.<\/li>\n<li>Villanueva A, Llovet JM. Second-line therapies in HCC: emergence of resistance to sorafenib. <strong>Clin Cancer Res<\/strong> 2012;18:1824-26.<\/li>\n<li>Villanueva A, Forns X, Llovet JM. Molecular epidemiology in HCV-related hepatocellular carcinoma: first steps. <strong>J Hepatol<\/strong> 2012;57:213-214.<\/li>\n<li>Alsinet C, Villanueva A, Llovet JM. Cell population genetics and deep sequencing: a novel approach for drivers discovery in hepatocellular carcinoma. <strong>J Hepatol<\/strong> 2012;56:1198-200.<\/li>\n<li>Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Bruix J, Mazzaferro V, Friedman SL, Llovet JM. Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. <strong>J Hepatol<\/strong> 2012;56:1343-50.<\/li>\n<li>Hoshida Y, Moeini A, Alsinet C, Kojima K, Villanueva A. Gene signatures in the management of hepatocellular carcinoma. <strong>Semin Oncol<\/strong> 2012;39(4):473-85.<\/li>\n<li>Toffanin S, Sia D, Villanueva A. microRNAs: new ways to block tumor angiogenesis? <strong>J Hepatol<\/strong> 2012;57(3):490-1.<\/li>\n<li>Keng VW, Largaespada DA, Villanueva A. Why men are at higher risk for hepatocellular carcinoma? <strong>J Hepatol<\/strong> 2012;57:453-454.<\/li>\n<\/ul>\n<p><strong>2011<\/strong><\/p>\n<ul>\n<li>Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, Liberzon A, Kobayashi M, Kumada H, Thung S, Bruix J, Newell P, April C, Fan JB, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Llovet JM. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. <strong>Gastroenterology<\/strong> 2011;140:1501-12.<\/li>\n<li>Sia D, Villanueva A. Signaling pathways in hepatocellular carcinoma. <strong>Oncology<\/strong> 2011;81:18-23<\/li>\n<li>Villanueva A, Hoshida Y, Llovet JM. Hepatocellular carcinoma enters the sequencing era. \u2028<strong>Gastroenterology<\/strong> 2011;141:1943-5.<\/li>\n<li>Toffanin S, Hoshida Y, Lachenmayer A, Villanueva A, Cabellos L, Minguez B, Savic R, Ward SC, Thung S, Chiang DY, Alsinet C, Tovar V, Roayaie S, Schwartz M, Bruix J, Waxman S, Friedman SL, Golub T, Mazzaferro V, Llovet JM. <strong>Gastroenterology<\/strong> 2011;140:1618-28<\/li>\n<li>Villanueva A, Hoshida Y. Depicting the role of TP53 in hepatocellular carcinoma progression. \u2028<strong>J Hepatol <\/strong>2011;55:724-51.<\/li>\n<li>Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. <strong>Gastroenterology<\/strong> 2011;140:1410-26.<\/li>\n<li>Minguez B, Hoshida Y, Villanueva A, Toffanin S, Cabellos L, Thung S, Mandeli J, Sia D, April C, Fan JB, Lachenmayer A, Savic R, Roayaie S, Mazzaferro V, Bruix J, Schwartz M, Friedman SL, Llovet JM. Gene-expression signature of vascular invasion in hepatocellular carcinoma. <strong>J Hepatol<\/strong> 2011;55:1325-31.<\/li>\n<li>Cornella H, Alsinet C, Villanueva A. Molecular pathogenesis of hepatocellular carcinoma. \u2028<strong>Alcohol Clin Exp Res<\/strong> 2011;35:821-5.<\/li>\n<li>Tarocchi M, Hannivoort R, Hoshida Y, Lee UE, Vetter D, Narla G, Villanueva A, Oren M, Llovet JM, Friedman SL. Carcinogen-induced hepatic tumors in KLF6+\/- mice recapitu- late human hepatocellular carcinoma, associated with p53 pathway deregulation. <strong>Hepatology<\/strong> 2011;54:522-31.<\/li>\n<\/ul>\n<p><strong>2010<\/strong><\/p>\n<ul>\n<li>Tovar V, Alsinet C, Villanueva A, Chiang DY, Sole M, Thung S, Moyano S, Toffanin S, Minguez B, Cabellos L, Peix J, Schwartz M, Mazzaferro V, Bruix J, Llovet JM. IGF pathway deregulation in early HCC and pre-clinical efficacy of blocking IGF1R. <strong>J Hepatol<\/strong> 2010;52:550-559.<\/li>\n<li>Toffanin S, Villanueva A, Llovet JM. miRNA delivery: emerging therapy for HCC. <strong>Gastroenterology<\/strong> 2010;138:1202-1204.<\/li>\n<li>Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel \u2028molecular approaches for diagnosis, prognosis, and therapy. <strong>Annu Rev Med<\/strong> 2010;61:317-28<\/li>\n<li>Cornella H, Villanueva A. Genomic tracing of the elusive liver cancer ancestor. <strong>J Hepatol<\/strong> \u20282010;53:578-9.<\/li>\n<li>Zender L, Villanueva A, Tovar V, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. <strong>J Hepatol <\/strong>2010;52:921-29.<\/li>\n<li>Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: Genomic Prognostic Markers. <strong>Clin Cancer Res<\/strong> 2010;16:4688-94.<\/li>\n<li>Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet JM. Molecular classification and novel targets in hepatocellular carcinoma: recent advances. <strong>Semin Liver Dis<\/strong> 2010;30:35-51.<\/li>\n<li>Villanueva A, Newell P, Hoshida Y. Inherited hepatocellular carcinoma. <strong>Best Pract Res Clin Gastroenterol <\/strong>2010;24:725-34.<\/li>\n<\/ul>\n<p><strong>2009<\/strong><\/p>\n<ul>\n<li>Keng V, Villanueva A, Chiang D, Starr T, Silverstein K, Akagi K, Tessarollo L, Matise I, Sarver A, Powers S, Lowe S, Collier L, Dupuy A,Jenkins N,. Copeland N, Llovet JM, Largaespada DA. LE: A condicional transposon-based insertional mutagenesis system for modeling human cancer in mice.<strong> Nat Biotechnol<\/strong> 2009;27:264-74.<\/li>\n<li>Villanueva A, Savic R, Llovet JM. Lymphotoxins: new targets for hepatocellular carcinoma. <strong>Cancer Cell<\/strong> 2009;16:272-3.<\/li>\n<li>Minguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. <strong>Curr Opin Gastroenterol <\/strong>2009;25:186-94.<\/li>\n<li>Yoo B, Emdad L, Su Z, Villanueva A, Chiang DY, Mills AS, Waxman S, Fisher R, Llovet JM, Fisher P, Sarkar D. Astrocyte elevated gene\u20131 regulates hepatocellular carcinoma development and progression. <strong>J Clin Invest<\/strong> 2009;19:465-77.<\/li>\n<li>Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel M, Thung S, Alsinet C, Tovar V, Hoshida Y, Bruix J, Roayaie S, Mazzaferro V, Schwartz M, Friedman S, Llovet JM. Ras pathway activa- tion in hepatocellular carcinoma and anti-tumoral effect of double blockage with Sorafenib and Rapamycin in vivo. <strong>J Hepatol<\/strong> 2009;51:725-33.<\/li>\n<li>Hoshida Y, Villanueva A, Llovet JM. Molecular profiling to predict hepatocellular carcinoma outcome. <strong>Expert Rev Gastroenterol Hepatol<\/strong> 2009;3:101-3.<\/li>\n<li>Hoshida Y, Nijman S, Kobayashi M, Chan J, Jean- Brunet P, Chiang DY, Villanueva A, Newell P,Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. <strong>Cancer Res<\/strong> 2009;69:7385-92.<\/li>\n<\/ul>\n<p><strong>2008<\/strong><\/p>\n<ul>\n<li>Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, Van Laarhoven S, Fiel MI, Di Feo A, Hoshida Y, Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal role of mTOR signaling in hepatocellular carcinoma. <strong>Gastroenterology<\/strong> 2008;135:1972-83.<\/li>\n<li>Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang D, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan J, Ikeda K, Hashimoto M, Watanabe G, Roayaie S, Schwartz M, Thung S, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression profiles of adjacent liver predict outcome in hepatocellular carcinoma. <strong>N Engl J Med<\/strong> 2008;359:1995-04.<\/li>\n<li>Newell P, Villanueva A, FriedmanS, Koike K, and Llovet JM. Experimental models in hepa- tocellular carcinoma. <strong>J Hepatol<\/strong> 2008;48:858-79.<\/li>\n<li>Newell P, Villanueva A, Llovet JM. Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials. <strong>J Hepatol<\/strong> 2008;49:1-5.<\/li>\n<li>Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E, Villanueva A, Loke J, Akita K, Shira- sawa S, Sasazuki T, Margignetti J, Llovet JM, Friedman SL. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. <strong>Gastroenterology<\/strong> 2008;134:1521-31.<\/li>\n<li>Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF signaling. <strong>Mol Cancer Ther<\/strong> 2008;7:3129-40.<\/li>\n<li>Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. <strong>Curr Opin Oncol<\/strong> 2008;20:444-45.<\/li>\n<li>Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, Leblanc AC, Donovan DJ, Thung SN, Sole M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M, Llovet JM. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. <strong>Cancer Res<\/strong> 2008;68:6779-88.<\/li>\n<\/ul>\n<p><strong>2007 &amp; before<\/strong><\/p>\n<ul>\n<li>Villanueva A, Newell P, Chiang D, Friedman S, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. <strong>Semin Liver Dis<\/strong> 2007;27:55-76.<\/li>\n<li>Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma: an update analysis of randomized controlled trials. <strong>Aliment Pharmacol Ther<\/strong> 2006;23:1535-47.<\/li>\n<li>Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. <strong>Liver Transpl<\/strong> 2006;12:1747-54.<\/li>\n<li>Llovet JM, Chen Y, Wurmbach W, Roayaie S, Fiel I, Schwartz M, Thung S, Khitrov G, Zhang W, Villanueva A, Battiston C, Mazzaferro V, Bruix J, Waxman S, Friedman SL. A molecular sig- nature to discriminate dysplastic nodules and early hepatocellular carcinoma in HCV-cirrhosis. <strong>Gastroenterology<\/strong> 2006;6:1758-67.<\/li>\n<li>Dominguez-Munoz JE, Villanueva A, Larino J, Mora T, Barreiro M, Iglesias-Canle J, Iglesias- Garcia J. Accuracy of plasma levels of polymorphonuclear elastase as early prognostic marker of acute pancreatitis in routine clinical conditions. <strong>Eur J Gastroenterol Hepatol<\/strong> 2006;18:79-83.<\/li>\n<li>Castroagudin JF, Delgado M, Villanueva A, Bustamante M, Martinez J, Otero E, Tome S, Martinez SM, Segade FR, Conde R, Dominguez-Munoz E, Varo E. Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. <strong>Transplant Proc<\/strong> 2005;37:3871-3.<\/li>\n<li>Villanueva A, Dominguez-Munoz JE, Mearin F. Update in the therapeutic management of irritable bowel syndrome. <strong>Dig Dis<\/strong> 2001;19:244-50.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>\u00a0 2019 Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019 (in press) Kenny TC, Craig AJ, Villanueva A, Germain D. Mitohormesis primes tumor invasion and metastasis. Cell Reports 2019 (in press) DeRossi C, Bambino K, Morrison J, Sakarin I, Villacorta-Martin C, Zhang C, Ellis JL, Fiel MI, Ybanez M, Lee YA, Huang KL, Yin [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"open","ping_status":"open","template":"","meta":{"footnotes":""},"class_list":["post-20","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-json\/wp\/v2\/pages\/20","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-json\/wp\/v2\/comments?post=20"}],"version-history":[{"count":20,"href":"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-json\/wp\/v2\/pages\/20\/revisions"}],"predecessor-version":[{"id":267,"href":"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-json\/wp\/v2\/pages\/20\/revisions\/267"}],"wp:attachment":[{"href":"https:\/\/labs.icahn.mssm.edu\/villanueva-lab\/wp-json\/wp\/v2\/media?parent=20"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}